The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2017 | Current standard of care for patients who are eligible for autologous stem cell transplantation
Michele Cavo, MD, from the Bologna University School of Medicine, Bologna, Italy, discusses the current standard of care for patients who are eligible to receive autologous stem cell transplantation at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. The standard of care for patients who are eligible to receive a stem cell transplant is a three-drug regimen incorporating bortezomib. Daratumumab is currently not approved for recently diagnosed patients, however, there are ongoing clinical trials evaluating the possibility of its addition to the current three drug regimen. In the future, the standard of care might change to a four-drug regimen instead, incorporating a monoclonal antibody and a proteasome inhibitor, provided that the toxicity profile is low.
